Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

By Swisher E.M.   Mutch D.G.   Rader J.S.   Elbendary A.   Herzog T.J.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 480-486

Elsevier

Access to resources Recommend Favorite

Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma

By Sorensen P.   Hoyer M.   Jakobsen A.   Malmstrom H.   Havsteen H.   Bertelsen K.  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 58-62

Elsevier

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Verschraegen C.F.   Westphalen S.   Hu W.   Loyer E.   Kudelka A.   Volker P.   Kavanagh J.   Steger M.   Schulz K.-D.   Emons G.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 552-559

Elsevier

Access to resources Recommend Favorite

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum

By du Bois A.   Luck H.J.   Buser K.   Meerpohl H.G.   Sessa C.   Klaassen U.   Meden H.   Bochtler H.   Diergarten K.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 379-384

Elsevier

Access to resources Recommend Favorite